U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07374848) titled 'Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors' on Dec. 15, 2025.
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Sarcomas
Intervention:
DRUG: ZL-6201
ZL-6201 as a single-agent
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Zai Lab (Shanghai) Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....